Key Performance Data Summary Performance Summary Performance Indicator Measure 22/23 23/24 24/25 More in 24/25 Annual Report (page reference) Operating revenue US$ million 13,310¶^ 14,800¶^ 15,558¶^ 90 Net profit US$ million 2,194¶^ 2,642¶^ 3,002¶^ 90 Economic value generated* US$ million 13,348†^ 14,839#^ 15,596#^ Economic value distributed* US$ million 13,209†^ 13,516#^ 14,066#^ 27 Promising Futures CSL’s people Total workforce Number 32,065†^ 32,698#^ 29,904#^ CGS 11 Total Board female Percentage 44†^ 56#^ 60#^ Total workforce female Percentage 59†^ 59#^ 56.5#^ CGS 11 Total people managers female Percentage 45†^ 46#^ 45.9#^ CGS 11 Total senior executives female Percentage 32†^ 34#^ 36.3#^ CGS 11 Total Recordable Injury Frequency Rate (TRIFR) Per million hours worked for Non‑CSL Plasma sites 0.94†^ 0.70#^ 0.62#^ 34 Per million hours worked for CSL Plasma 12.1† 9.75#^ 6.90#^ 34 Fatalities (employees and contingent workers) Number 0†^ 0#^ 0#^ 34 Employee engagement Percentage 76.2†^ 74.8#^ 72.9#^ 8 ESG employee engagement** Percentage 76.2†^ 75.1#^ 75.9#^ Healthier Communities Innovation R&D investment US$ million 1,266†^ 1,428¶^ 1,359¶^ 106 Clinical trials in operation Number 60 60 59 30 Safety and quality Regulatory audits of manufacturing facilities and plasma collection centres Number 475†^ 479#^ 403#^ 33 Safety related recalls of finished product†† Number 3†^ 2#^ 2#^ 33 Community Total contribution US$ million 42.6 45.3 35.4 27 Product access support (subset of total community contribution)*** US$ million 13.7† 15.7# 16.5# 27 Plasma donors willing to donate again Percentage 94† 94# 93# 33 CGS = Corporate Governance Statement which can be accessed at https://www.csl.com/we-are-csl/corporate-governance. 141 CSL Limited Annual Report 2024/25
RkJQdWJsaXNoZXIy MjE2NDg3